beta blockers and glp-1 Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond The Role of GLP-1RA Medications

Oral doses can start at 300mg per day and go up depending on individual requirement

Disease-associated glia in neurodegenerative diseases Chronic inflammatory responses and disease-associated glia are well known to contribute to the development of various neurodegenerative diseases

Shah TJ, Moshirfar M, Hoopes PC (2018) Doctor, I have a sulfa allergy: clarifying the myths of cross-reactivity

Originally developed for diabetes, then approved for obesity, and now showing promise for various psychiatric conditions including binge eating disorder, substance use disorders, and possibly depression itself

Both drugs may also curb hunger and food cravings